• TD Securities (USA), BofA Securities, Goldman Sachs & Co., Santander US Capital Markets and SG Americas Securities as lead managers on an SEC-registered offering by TD Bank of $3.3 billion aggregate principal amount of senior notes.
• Wells Fargo Securities, BofA Securities and Goldman Sachs & Co. as representatives of the underwriters in connection with the offering of $1 billion aggregate principal amount of senior notes issued by Lockheed Martin.
• Ventas in connection with the execution of a forward sale agreement with an affiliate of Wells Fargo Securities relating to an aggregate of 10,600,000 shares of its common stock. In connection with the forward sale agreement, Wells Fargo Securities (or its affiliate) borrowed an aggregate of 10,600,000 shares of Ventas’ common stock from third parties for sale in an SEC-registered public offering. Ventas will receive net proceeds of approximately $675.3 million, before offering expenses and subject to certain adjustments, upon physical settlement of the forward sale agreement.
• BofA Securities and UBS Securities, as joint book-running managers and representatives of the initial purchasers on a debut Rule 144A/Regulation S offering by Horizon Mutual Holdings, of $600 million aggregate principal amount of its 6.200% senior notes due 2034.
• Morgan Stanley & Co., UBS Securities, Piper Sandler & Co. and Raymond James & Associates, as representatives of the several underwriters, in connection with Merchants Bancorp’s SEC-registered offering of 9,200,000 depositary shares, each representing a 1/40th interest in a share of its 7.625% fixed-rate Series E non-cumulative perpetual preferred stock, without par value per share, with a liquidation preference of $25 per depositary share (equivalent to $1,000 per share of Series E preferred stock). The gross proceeds from the offering totaled approximately $230 million.

• Morgan Stanley & Co. and Allen & Company, as underwriters, in connection with the $232.3 million public offering by Joby Aviation, of 46,000,000 SEC-registered shares of common stock, which includes the exercise in full by the underwriters of their option to purchase additional shares.
• J.P. Morgan Securities, Barclays Capital and Mizuho Securities USA, as representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by NCL Corporation (NCLC), a wholly owned subsidiary of Norwegian Cruise Line Holdings (NCLH), of $315 million aggregate principal amount of senior notes.
• BofA Securities, J.P. Morgan Securities and Wells Fargo Securities, as joint representatives of the underwriters on an SEC-registered offering by W.W. Grainger, of $500 million aggregate principal amount of senior notes.
• TD Securities (USA) as representative of the several underwriters on an SEC-registered offering by TD Bank of $1 billion aggregate principal amount of 5.146% non-viability contingent capital subordinated notes due 2034.
• Royalty Pharma in connection with its SEC-registered offering of $1.5 billion aggregate principal amount of senior notes. BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, Morgan Stanley & Co. and TD Securities (USA) acted as representatives of the several underwriters in connection with the offering.
• The underwriters in connection with an SEC-registered offering of €3 billion aggregate principal amount of notes by Medtronic Inc. Medtronic plc is the indirect parent company of Medtronic Inc.
• TD Securities (USA), Citigroup Global Markets, J.P. Morgan Securities, Lloyds Securities and SG Americas Securities, as lead managers on an SEC-registered offering by TD Bank of $2.25 billion aggregate principal amount of its senior notes.
• J.P. Morgan Securities, as sole book-running manager and underwriter in connection with an upsized public offering by Stoke Therapeutics, of 5,555,557 shares of common stock at $13.5000 per share and pre-funded warrants to purchase 3,703,730 shares of common stock at $13.4999 per pre-funded warrant, for total gross proceeds of approximately $125 million.
• Morgan Stanley & Co., Goldman Sachs & Co., Barclays Capital and Stifel, Nicolaus & Co., as joint book-running managers and representatives of the several underwriters in connection with a public offering by REGENXBIO  of 4,565,260 shares of common stock at $23.00 per share and pre-funded warrants to purchase 1,521,740 shares of common stock at $22.9999 per pre-funded warrant, for total gross proceeds of approximately $140 million.
• Deutsche Bank Securities, Goldman Sachs & Co., J.P. Morgan Securities and Wells Fargo Securities, as representatives of the several underwriters in connection with the SEC-registered offering of $4.5 billion aggregate principal amount of senior notes by the Cigna Group.
• Citizens JMP Securities as the underwriter in connection with a $65 million public offering of 5,750,000 shares of Class A common stock of Perella Weinberg Partners.
• Deutsche Bank Securities, Goldman Sachs & Co., J.P. Morgan Securities and Wells Fargo Securities, as representatives of the several underwriters in connection with the SEC-registered offering of $4.5 billion aggregate principal amount of senior notes by the Cigna Group, and J.P. Morgan Securities, Deutsche Bank Securities, Goldman Sachs & Co. and Wells Fargo Securities, as the dealer managers of Cigna’s cash tender offers for certain senior notes of Cigna and its subsidiaries.
• Morgan Stanley & Co., Mizuho Securities USA and SMBC Nikko Securities America, as representatives of the underwriters in connection with the offering of $2 billion aggregate principal amount of senior notes issued by Lockheed Martin.
• BofA Securities, as representative of the initial purchasers in connection with a Rule 144A / Regulation S offering by Chobani, and Chobani Finance,  of $500 million aggregate principal amount of their 7.625% senior notes due 2029.
• Morgan Stanley & Co., as (i) representative of the several underwriters in connection with a registered public offering by Spirit AeroSystems Holdings, of up to 10,454,545 shares of its Class A common stock and (ii) representative of the several initial purchasers in connection with a Rule 144A offering by Spirit AeroSystems, pursuant to which it issued $230 million aggregate principal amount of 3.250% exchangeable senior notes due 2028.
• J.P. Morgan Securities, Barclays Capital and Mizuho Securities USA, as representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by NCL Corporation (NCLC), a wholly owned subsidiary of Norwegian Cruise Line Holdings (NCLH), of $790 million aggregate principal amount of its 8.125% senior secured notes due 2029.
• Morgan Stanley & Co. as the representative of the initial purchasers in connection with a Rule 144A offering by Seagate HDD Cayman, pursuant to which it issued $1.5 billion aggregate principal amount of 3.50% exchangeable senior notes due 2028. 
  TD Securities (USA), Citigroup Global Markets, Goldman Sachs & Co., NatWest Markets Securities and Standard Chartered Bank as lead managers on an SEC-registered offering by TD Bank of $5.2 billion aggregate principal amount of its senior notes.
• Morgan Stanley & Co., as the representative of the initial purchasers in connection with Rule 144A/Regulation S offerings by Seagate HDD Cayman, pursuant to which it issued $1.0 billion aggregate principal amount of senior notes. The notes are unconditionally guaranteed by Seagate Technology Holdings and Seagate Technology Unlimited.
• Citigroup Global Markets, Barclays Capital and Credit Agricole Securities (USA) as representatives of the underwriters in connection with the offering of $2 billion aggregate principal amount of senior notes issued by Lockheed Martin.
• Barclays Capital, J.P. Morgan Securities and Mizuho Securities USA as the representatives of the several underwriters in connection with an SEC-registered offering of $2 billion aggregate principal amount of notes by Medtronic Global Holdings S.C.A.
• Marsh McLennan in connection with its SEC-registered offering of $600 million of its senior notes.
• BofA Securities, Morgan Stanley & Co. and U.S. Bancorp Investments, as representatives of the several underwriters in connection with the SEC-registered offering of $1.5 billion aggregate principal amount of senior notes by the Cigna Group.
• CureVac on its $250 million public offering of 27,027,028 common shares.
• J.P. Morgan Securities and Mizuho Securities USA, as representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by NCL Corporation Ltd. (NCLC), a wholly owned subsidiary of Norwegian Cruise Line Holdings (NCLH), of $600 million aggregate principal amount of senior secured notes.
• Morgan Stanley & Co., MUFG Securities Americas, BofA Securities, Scotia Capital (USA), Wells Fargo Securities and BNP Paribas Securities as the lead dealer managers, in connection with a Rule 144A/Regulation S exchange offers by Seagate HDD Cayman.
• Barclays Capital, BofA Securities, Citigroup Global Markets, J.P. Morgan Securities and MUFG Securities Americas, as joint book-running managers, in connection with an SEC-registered offering by Zoetis of $600 million aggregate principal amount of its 5.400% senior notes due 2025 and $750 million aggregate principal amount of its 5.600% senior notes due 2032.
• Barclays Bank, BofA Securities Europe, Citigroup Global Markets and HSBC Continental Europe as representatives of the several underwriters in connection with an SEC-registered offering of €3.5 billion aggregate principal amount of notes by Medtronic Global Holdings S.C.A.
• J.P. Morgan Securities, as representative of the initial purchasers in connection with a Rule 144A offering by Alnylam Pharmaceuticals,  of $1.035 billion aggregate principal amount of its 1.00% convertible senior notes due 2027, including $135 million principal amount of convertible notes pursuant to the exercise in full of the initial purchasers’ option to purchase additional convertible notes.
• BofA Securities, as representative of the underwriters in connection with an SEC-registered offering by YUM! Brands, of $1 billion aggregate principal amount of 5.375% senior notes due 2032.
• J.P. Morgan Securities, Goldman Sachs & Co. and Mizuho Securities USA, as representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by NCL Corporation (NCLC), a wholly owned subsidiary of Norwegian Cruise Line Holdings (NCLH), of $1 billion aggregate principal amount of its 5.875% senior secured notes due 2027 and of $600 million aggregate principal amount of its 7.750% senior unsecured notes due 2029.
• J.P. Morgan Securities, Goldman Sachs & Co. and Mizuho Securities USA, as representatives of the initial purchasers in connection with a Rule 144A offering by NCL Corporation (NCLC), a wholly owned subsidiary of Norwegian Cruise Line Holdings (NCLH), of $435 million aggregate principal amount of its 2.50% exchangeable senior notes due 2027.
• Wells Fargo Securities, as representative of the several initial purchasers in connection with a Rule 144A/Regulation S offering by Range Resources of $500 million principal amount of its 4.75% senior notes due 2030. The notes are guaranteed by each of Range Resources’ subsidiaries.
• Morgan Stanley & Co. as underwriter in connection with the $351 million block trade of 8,562,500 shares of Class A common stock of Warner Music Group Corp., sold by AI Entertainment Holdings, CT/FT Holdings and LB Remainder Holdings, the selling stockholders.
• BofA Securities Europe, Citigroup Global Markets and J.P. Morgan Securities as representatives of the several initial purchasers in connection with the Rule 144A / Regulation S offering by DXC Capital Funding DAC, an indirect subsidiary of DXC Technology, of €750 million aggregate principal amount of 0.450% senior notes due 2027 and €600 million aggregate principal amount of 0.950% senior notes due 2031; and BofA Securities, Citigroup Global Markets and J.P. Morgan Securities as representatives of the several underwriters in connection with the SEC-registered offering by DXC Technology of $700 million aggregate principal amount of 1.800% senior notes due 2026 and $650 million aggregate principal amount of 2.375% senior notes due 2028.
• MSCI in connection with a Rule 144A/Regulation S offering of $700 million aggregate principal amount of its 3.250% senior notes due 2033. The notes are guaranteed by certain subsidiaries of MSCI.
• The initial purchasers in a Rule 144A/Regulation S offering of €445 million principal amount of 2.250% senior secured notes due 2031 of WMG Acquisition, a subsidiary of Warner Music Group.
• Royalty Pharma on an SEC-registered offering of $1.3 billion aggregate principal amount of senior notes. The offering consisted of $600 million aggregate principal amount of 2.150% senior notes due 2031 (the “Social Bonds”) and $700 million aggregate principal amount of 3.350% senior notes due 2051.
• Charles River Laboratories International, in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 3.750% senior notes due 2029 and $500 million aggregate principal amount of 4.000% senior notes due 2031.
• BofA Securities, Goldman Sachs & Co. and Nomura Securities International, as representatives of the several underwriters in connection with the $684.7 million initial public offering by Hayward Holdings, of 40,277,778 shares of its common stock, of which 18,077,778 shares were sold by the selling stockholders.
• BofA Securities, as representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by TopBuild of $400 million aggregate principal amount of its 3.625% senior notes due 2029.
• CureVac on its $450 million public offering of 5,000,000 of its common shares.
• The initial purchasers in a Rule 144A/Regulation S offering of $250 million principal amount of 3.000% senior secured notes due 2031 of WMG Acquisition, a subsidiary of Warner Music Group Corp.
• Royalty Pharma and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling shareholders.
• Barclays Bank, BofA Securities Europe, Mizuho Securities Europe and Deutsche Bank Aktiengesellschaft as representatives of the several underwriters in connection with an SEC-registered offering of €6.25 billion aggregate principal amount of notes by Medtronic Global Holdings S.C.A. Medtronic Global Holdings S.C.A. is an indirect subsidiary of Medtronic plc.
• Royalty Pharma in connection with its Rule 144A/Regulation S offering of $6 billion aggregate principal amount of senior notes.
• CureVac on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares.
• Freeport-McMoRan in connection with its SEC-registered offering of $1.5 billion of senior notes.
• J.P. Morgan Securities, Citigroup Global Markets and Goldman Sachs & Co.  as representatives of the underwriters in connection with an SEC-registered offering by Norwegian Cruise Line Holdings of 19,166,667 of its ordinary shares that raised approximately $277 million in gross proceeds, and J.P. Morgan Securities, Citigroup Global Markets and Goldman Sachs & Co. as representatives of the initial purchasers in connection with a concurrent Rule 144A offering by NCL Corporation of $400 million aggregate principal amount of its 5.375% exchangeable senior notes due 2025, and J.P. Morgan Securities as representative of the initial purchasers in connection with a concurrent Rule 144A/Regulation S offering by NCLC of $750 million aggregate principal amount of its 10.250% senior secured notes due 2026.
• The initial purchasers in a Rule 144A/Regulation S offering of $535 million principal amount of 3.875% senior secured notes due 2030 of WMG Acquisition Corp., a subsidiary of Warner Music Group Corp.
• Morgan Stanley & Co., Barclays Capital, BofA Securities and J.P. Morgan Securities as joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650 million aggregate principal amount of 1.400% notes due 2030.
• Royalty Pharma and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares.
• Morgan Stanley & Co., Credit Suisse Securities (USA) and Goldman Sachs & Co. as representatives of the several underwriters, in connection with the $1.925 billion initial public offering of 77,000,000 shares of Class A common stock of Warner Music Group Corp., sold by the selling stockholders.
• Barclays Capital, BofA Securities, Citigroup Global Markets, J.P. Morgan Securities and MUFG Securities Americas, as joint book-running managers, in connection with an SEC-registered offering by Zoetis of $750 million aggregate principal amount of its 2.000% senior notes due 2030 and $500 million aggregate principal amount of its 3.000% senior notes due 2050.
• VF in connection with an SEC-registered debt shelf takedown of $3 billion aggregate principal amount of senior notes. Barclays, BofA Securities, J.P. Morgan, Morgan Stanley, HSBC, ING, US Bancorp and Wells Fargo Securities acted as joint book-running managers for the offering.
• BofA Securities, Citigroup Global Markets and MUFG Securities Americas as representatives of the several underwriters in connection with the registered offering by DXC Technology of $500 million aggregate principal amount of 4.000% senior notes due 2023 and $500 million aggregate principal amount of 4.125% senior notes due 2025.
• BofA Securities, Goldman Sachs & Co. and Morgan Stanley & Co. as representatives of the several underwriters in connection with the SEC-registered offering of $3.5 billion aggregate principal amount of senior notes; and BofA Securities, Goldman Sachs & Co. and Morgan Stanley & Co. as the dealer managers of Cigna’s cash tender offers for senior notes issued by Cigna and its subsidiaries.
• BofA Securities, J.P. Morgan Securities and Wells Fargo Securities, as representatives of the several initial purchasers, in a Rule 144A/Regulation S offering by Huntington Ingalls Industries, of $500 million aggregate principal amount of its 3.844% senior notes due 2025 and $500 million aggregate principal amount of its 4.200% senior notes due 2030.
• Charles River Laboratories International, in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes due 2028.

Matters may have been handled prior to joining Paul Hastings.